{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:30:48Z","timestamp":1792557048332,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA051008 [PI: LM Weiner]"],"award-info":[{"award-number":["P30CA051008 [PI: LM Weiner]"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["ML28685"],"award-info":[{"award-number":["ML28685"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012385","name":"Georgetown-Howard Universities Center for Clinical and Translational Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10549-019-05191-2","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T02:38:48Z","timestamp":1552099128000},"page":"595-603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study"],"prefix":"10.1007","volume":"175","author":[{"given":"F.","family":"Lynce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Barac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Herbolsheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"Srichai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hofmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Timothee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. M.","family":"Asch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shajahan-Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-3830","authenticated-orcid":false,"given":"S. M.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,9]]},"reference":[{"key":"5191_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"5191_CR2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"5191_CR3","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"5191_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283","journal-title":"N Engl J Med"},{"key":"5191_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783\u20131791","journal-title":"N Engl J Med"},{"key":"5191_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724\u2013734","journal-title":"N Engl J Med"},{"issue":"3","key":"5191_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G et al (2018) Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2- positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 29(3):646\u2013653","journal-title":"Ann Oncol"},{"issue":"8","key":"5191_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/07357907.2014.922570","volume":"32","author":"F Lynce","year":"2014","unstructured":"Lynce F, Swain SM (2014) Pertuzumab for the treatment of breast cancer. Cancer Invest 32(8):430\u2013438","journal-title":"Cancer Invest"},{"key":"5191_CR9","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in arandomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy is node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811\u20137819","journal-title":"J Clin Oncol"},{"key":"5191_CR10","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EH Romond","year":"2012","unstructured":"Romond EH, Jong JH, Rastoja P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide (AC) followed by paclitaxel to AC followed by paclitaxel plus trastuzumab as adjuvant therapy for patients with node-positive, HER2-positive breast cancer. J Clin Oncol 30:3792\u20133799","journal-title":"J Clin Oncol"},{"key":"5191_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant breast Cancer Trial. J Clin Oncol 26:1231\u20131238","journal-title":"J Clin Oncol"},{"issue":"9","key":"5191_CR12","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278\u20132284","journal-title":"Ann Oncol"},{"issue":"2","key":"5191_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchf.2017.08.024","volume":"6","author":"B Kenigsberg","year":"2018","unstructured":"Kenigsberg B, Wellstein A, Barac A (2018) Left ventricular dysfunction in cancer treatment: is it relevant? JACC Heart Fail 6(2):87\u201395","journal-title":"JACC Heart Fail"},{"key":"5191_CR14","unstructured":"Herceptin [package insert]. San Francisco, CA: Genentech, Inc., 2015"},{"key":"5191_CR15","unstructured":"Kadcyla [package insert]. San Francisco, CA: Genentech, Inc., 2016"},{"key":"5191_CR16","unstructured":"Perjeta [package insert]. San Francisco, CA: Genentech, Inc., 2016"},{"key":"5191_CR17","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J ClinOncol 23:7820\u20137826","journal-title":"J ClinOncol"},{"key":"5191_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1634\/theoncologist.2015-0125","volume":"20","author":"AF Yu","year":"2015","unstructured":"Yu AF, Yadav NU, Eaton AA et al (2015) Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Oncologist 20:1105\u20131110","journal-title":"Oncologist"},{"key":"5191_CR19","doi-asserted-by":"crossref","unstructured":"Lynce F, Barac A, Tan MT et al., SAFE-HEART: SAFE-HEaRt: rationale and design of a pilot study investigating cardiac safety of HER2 targeted therapy in patients with HER2-positive breast cancer and reduced left ventricular function. Oncologist 2017;22(5):518\u2013525","DOI":"10.1634\/theoncologist.2016-0412"},{"issue":"1","key":"5191_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1\u201339.e14","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"5191_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Amenian","year":"2017","unstructured":"Amenian SH, Lacchetti C, Barac A et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35(8):893\u2013911","journal-title":"J Clin Oncol"},{"key":"5191_CR22","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671\u20131680","journal-title":"Eur Heart J"},{"key":"5191_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S et al (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870\u2013876","journal-title":"J Clin Oncol"},{"issue":"7","key":"5191_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.echo.2009.05.020","volume":"22","author":"PS Douglas","year":"2009","unstructured":"Douglas PS, DeCara JM, Devereux RB et al (2009) Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. J Am Soc Echocardiogr 22(7):755\u2013765","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"5191_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.echo.2017.11.018","volume":"31","author":"MG Khouri","year":"2018","unstructured":"Khouri MG, Ky B, Dunn G et al (2018) Echocardiography core laboratory reproducibility of cardiac safety assessments in cardio-oncology. J Am Soc Echocardiogr 31(3):361\u2013371","journal-title":"J Am Soc Echocardiogr"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05191-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T09:14:41Z","timestamp":1589706881000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05191-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5191"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05191-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,9]]},"assertion":[{"value":"25 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.L. reports personal fees from AstraZeneca, Celgene, Jounce; research grants to institution from Bristol-Myers Squibb, Calithera, Chugai, Genentech\/Roche, Immunomedics, Inivata, Pfizer, Regeneron, Tesaro. C.D. reports personal fees from Amgen, Pfizer, Puma Biotechnology, Roche\/Genentech; research grants from Amgen, Pfizer, Puma Biotechnology, Roche\/Genentech. A.B. reports honoraria from Bristol-Myers Squibb. A.F.U. reports personal fees from Glenmark Pharmaceuticals. KLS reports ownership interest in AbbVie, Abbott Laboratories; honoraria from ASiM CME; research grants to self from Pfizer\/NCCN and to institution from AstraZeneca, Pfizer, Galena BioPharma, Novartis, Pfizer, Syndax. P.R.P. reports ownership interest in Immunonet BioSciences; personal fees from Genentech\/Roche, Heron Therapeutics, Immunonet BioSciences, OncoPlex Diagnostics, Personalized Cancer Therapy, Pfizer, Puma Biotechnology; research grants to institution from Advanced Cancer Therapeutics, Caris Centers of Excellence, Cascadian Therapeutics, Fabre-Kramer, Genentech\/Roche, Pfizer, Pieris Pharmaceuticals; and payments for patents, royalties, or other intellectual property for U.S. Patent Nos. 8,486,413; 8,501,417; 9,023,362; and 294 9,745,377. R.N. reports personal fees from Bristol-Myers Squibb; travel and accommodation from Bristol-Myers Squibb, Caris Life Sciences. P.H. reports employment by AstraZeneca; C.I. reports honoraria from AstraZeneca, Genentech, Roche; personal fees from AstraZeneca, Genentech, NanoString Technologies, Novartis, Pfizer, Puma Biotechnology, Syndax; speakers\u2019 bureau payments from AstraZeneca, Genentech, Pfizer; research grants to institution from Genentech, Novartis, Pfizer, Tesaro; and payments for patents, royalties, or other intellectual property from UpToDate, McGraw Hill. S.M.S. reports honoraria from Novartis, personal fees from Cardinal Health, Daiichi-Sankyo, Eli Lilly & Co., Genentech\/Roche, Genomic Health, Inivata, Peiris Pharmaceuticals, Tocagen; research grants to institution from Genentech; travel and accommodation from Caris Centers of Excellence, Daiichi-Sankyo, Eli Lilly & Co., Genentech\/Roche, NanoString Technologies; payments for participation on OlympiA IDMC from AstraZeneca. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}